Charles River agrees $470m deal for Frontage assets

Charles River Laboratories (CRL) agreed to acquire Frontage Holdings' bioanalysis and DMPK operations for $470M in cash, with up to $75M in earnouts. The deal includes two testing facilities and 340 employees, aiming to balance CRL's lab portfolio. CRL expects the acquisition to be neutral to non-GAAP EPS in 2027, then accretive. Analysts view it as a strategic addition, aligning with CRL's growth priorities. CRL shares were down 2.51% at $344.47 at the time of publication.

Charles River Laboratories (CRL) will acquire Frontage Holdings' bioanalysis and DMPK operations in Pennsylvania for up to $545 million in cash, including up to $75 million in performance-based payments. The deal, expected to close in early 2027, will expand CRL's clinical bioanalysis capabilities and support its growth strategy. Financing will come from CRL's credit facility and available cash.

Charles River Laboratories (CRL) will acquire Frontage's bioanalysis and DMPK operations for $470M in cash. The deal is expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter. The market for these services is projected to grow from $6B in 2026 to $8B-$9B by 2031, with annual growth of 6%-8%.

Charles River Laboratories agreed to buy Frontage's Exton bioanalysis and DMPK operations for $470 million in cash, with up to $75 million in potential performance-based payments. The deal, expected to close in the first half of 2027, includes two sites and 340 employees. It is projected to be neutral to non-GAAP EPS in 2027 and accretive thereafter, according to the company.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES TO ACQUIRE FRONTAGE’S BIOANALYSIS AND DMPK BUSINESSES – Strengthens Charles River's Bioanalysis and DMPK Capabilities to Support Clients Across the Drug Development Lifecycle – – Advances Pathway to Purpose Strategy and Enhance

Charles River Laboratories (CRL) agreed to acquire Frontage's bioanalysis and DMPK operations for ~$470M in cash, with up to $75M in performance-based payments. The deal, expected to close in H1 2027, is subject to approvals and other conditions. According to CRL, this acquisition will expand its clinical bioanalysis capabilities.